Notícias

As we execute on the strongest pipeline in our history, Gilead Sciences, Inc. is also taking steps to further strengthen the company's position for the future. The ongoing success of the Esthugo launch is a key driver of this growth in HIV prevention, with first quarter sales growing 72% sequentially. Looking forward, with no major LOEs until 2036, Gilead Sciences, Inc.'s HIV business is poised for strong, durable growth supported by up to seven potential new HIV product launches by 2033.

Gilead Sciences (NASDAQ:GILD) reported first-quarter 2026 results highlighted by growth in its base business, a higher full-year revenue outlook, and multiple late-stage pipeline and launch milestones across HIV, oncology, liver disease, and inflammation. Executives repeatedly pointed to “consistent

Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Gilead (GILD) delivered earnings and revenue surprises of +7.68% and +0.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences beat analysts’ earnings and revenue expectations in its latest quarter. Gilead logged adjusted earnings of $2.03 a share, ahead of the $1.91 consensus among analysts polled by FactSet. Gilead’s top-line growth rested heavily on Biktarvy, its blockbuster HIV treatment, which accounted for nearly half of total revenue as sales rose 8% to $3.4 billion.

Galapagos (NASDAQ:GLPG) executives used the company’s first-quarter 2026 earnings call to highlight what Chief Executive Officer Henry Gosebruch described as a “real transformation,” including portfolio changes, management and board updates, and an upcoming corporate rebrand to Lakefront Biotherapeu